Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Solid Cancers 1Sezary Syndrome 1Polycystic Ovary Syndrome 1Pituitary Neoplasms 1Pituitary ACTH Hypersecretion 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Follicular 1Central Nervous System Neoplasms 1Alzheimer Disease 1

Interventions

Rituximab 131Cyclophosphamide 74fludarabine phosphate 51Whole-Body Irradiation 38Peripheral Blood Stem Cell Transplantation 36Mycophenolic Acid 36Tacrolimus 32Etoposide 28Busulfan 28Melphalan 24Lenalidomide 23Prednisone 22Filgrastim 22Cyclosporine 22Bortezomib 22Antilymphocyte Serum 21Vincristine 19Methotrexate 19obinutuzumab 17Bendamustine Hydrochloride 16fludarabine 15Doxorubicin 15Radiotherapy 14ibrutinib 13Dexamethasone 13Cytarabine 13Cord Blood Stem Cell Transplantation 13Carmustine 13pembrolizumab 12idelalisib 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Lymphoma, Follicular × Rosiglitazone × Clear all
NCT00428090 2017-05-19

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

GlaxoSmithKline

Phase 3 Completed
862 enrolled 36 charts
Lymphoid

Alzheimer Disease, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡